Johnson & Johnson Valuation Exceeds 21x Forward EPS After 50% Rally
Analysts downgraded Johnson & Johnson to Hold after shares surged over 50% in the past year, pushing valuation above 21x forward EPS versus its long-term average. The company reported Q3 revenue of $24 billion with a 69.6% gross margin, raised FY25 sales guidance and maintained its operational EPS forecast.
1. Q4 Earnings Preview and Analyst Forecast Revisions
Johnson & Johnson will report fourth-quarter results before the market opens on Wednesday, January 21. Over the past two weeks, three of Wall Street’s most accurate earnings forecasters have adjusted their full-year 2026 EPS projections by an average of 3.2%, reflecting upgraded estimates in pharmaceuticals driven by stronger‐than‐expected demand for recent immunology launches. Consensus revenue forecasts for Q4 now stand at approximately $25.8 billion, up from $25.4 billion at the start of January, as upbeat guidance from peer MedTech providers signals resilient device sales. Analysts expect segment gross margins to expand by 50 basis points year-over-year, supported by ongoing cost‐savings initiatives and favorable foreign exchange movements.
2. Income Generation Strategies Ahead of Q4 Results
Options strategists targeting a $500 monthly income from J&J shares have focused on selling covered calls and cash-secured puts. With average implied volatility at 22.5% over the past 30 days, at-the-money call option premiums for February expirations have delivered yields near 4.8% annualized on a notional basis. Meanwhile, put premium receipts equivalent to a 4.2% yield have attracted income-oriented investors willing to assume potential assignment. These strategies hinge on managing risk around the upcoming earnings release and anticipated post-print swings of up to 5% intraday, based on historical J&J trading patterns in the two days following quarterly announcements.
3. Valuation Reassessment and ‘Hold’ Recommendation
Following a 50% gain in the past 12 months, J&J shares now trade above 21 times forward earnings, surpassing the company’s five-year average multiple of 17.8x. Despite robust fundamentals—third-quarter revenue of $24.0 billion (up 4.4% year-over-year), a 69.6% gross profit margin, and a raised full-year 2025 sales outlook—this premium valuation leaves limited margin of safety. As a result, several leading brokerages have downgraded their stance to Hold, citing stretched multiples and heightened competition in key biologics franchises such as the Stelara biosimilar segment and ongoing pricing pressure in Greater China markets.